Lv1
10 积分 2021-09-04 加入
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
15天前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
15天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
22天前
已完结
Genomic Characterization of Aggressive Breast Cancer in Younger Women
23天前
已完结
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
2个月前
已完结
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
2个月前
已完结
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
5个月前
已完结
Development of a Nomogram to Integrate Molecular Testing and Clinical Variables to Improve Malignancy Risk Assessment Among Cytologically Indeterminate Thyroid Nodules
6个月前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
8个月前
已完结
Clinical application of the AMOY 9-in-1 panel to lung cancer patients
8个月前
已完结
皖公网安备34019202002308
